Medtronic Affera milestones broaden PFA pipeline, but watchful wait remains

What happened

Medtronic announced at HRS that its Affera Sphere-9 catheter showed interim six-month success in VT patients, earning a Breakthrough Device designation and FDA approval for a U.S. pivotal trial, while the Sphere-360 catheter demonstrated consistent durability across anatomies and received CE Mark. The Conquer-AF trial has also started to evaluate Sphere-9 in repeat AFib procedures, expanding the addressable market beyond first-line paroxysmal AFib. These clinical milestones reinforce Medtronic's PFA leadership and support the company's strategy of building a comprehensive ablation platform with both focal and single-shot capabilities. However, the DeepValue master report maintains a WAIT rating at $95.60, citing a P/E of 26.6 and EV/EBITDA of 16.2 that already price in cardiovascular re-acceleration, while the Applied litigation treble-damages risk and impending Abbott Volt competition remain unresolved. The real test for the thesis will be FY26 Q4 earnings on May 20, 2026, when investors need to see sustained share gains without pricing pressure to justify current multiples.

Implication

The Affera milestones de-risk the PFA pipeline and expand total addressable market into VT and repeat AFib, strengthening Medtronic's competitive positioning against Boston Scientific and Abbott. However, the stock already reflects a successful PFA narrative at 26.6x earnings, leaving little room for execution missteps. The Applied $382M treble-damages verdict and Abbott Volt's commercial ramp remain unresolved, with the next critical checkpoint being FY26 Q4 results on May 20, 2026. Investors should wait for evidence that PFA share gains continue without pricing erosion and that litigation developments do not impair capital allocation. Until then, the implied base-value of $102 is offset by asymmetric downside risk, supporting a disciplined entry near $90 or after clarity on these key variables.

Thesis delta

The Affera clinical milestones strengthen the cardiovascular re-acceleration narrative but do not alter the base-case wait for FY26 Q4 confirmation and litigation resolution. The expansion into VT and repeat AFib broadens the pipeline optionality, yet competitive pressure from Abbott Volt and the Applied verdict remain the dominant near-term risks. The investment case still hinges on PFA pricing durability and cash flow visibility, with no change to the WAIT rating.